Clinical Trials

Clinical Trial Detail

Return to search results.

Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Complete title: A Phase 1/2 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies

Research Study Number       2724.00
    
Principal Investigator       Bill Bensinger, MD
    
Phase       I

Look up trial at NIH

Research Study Description

Primary Objective:

- To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984

Secondary Objectives:

- To characterize the global safety profile including cumulative toxicities

- To evaluate the pharmacokinetic (PK) profile of SAR650984 in the proposed dosing schedule(s)

- To assess the pharmacodynamics, immune response, and preliminary disease response

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.



Research Study Number       2724.00
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Hematologic Malignancies

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials